9888À­Ë¹Î¬¼Ó˹

DSPE-PEG2000-MAL£º¸³ÄÜin vivo CAR-TµÝË͵ÄÐÂ×¥ÊÖ

2025-11-04

×ÖºÅ

¡¡¡¡CAR-TÁÆ·¨ÊÇÈËÀàÔÚÉúÎïÒ½Ò©ÁìÓò¼ÌÓ×·Ö×Ó¡¢´ó·Ö×ÓÒÔÀ´£¬ÔÚϸ°û²ãÃæ»ñµÃµÄÓÖÒ»´Î¸ïÃüÐÔÍ»ÆÆ¡£Ìå±íCAR-T(ex vivo CAR-T)ÒÑÔÚBϸ°û°×Ѫ²¡ºÍÁÜ°ÍÁö´´ÏÂÁËÏÊÀöµÄÀï³Ì±®£¬µ«Æ临ÔÓµÄÔì×÷¹ý³Ì¡¢¸ß°ºµÄÓöȼ°¶¾ÐԵȾÖÏÞ³ÉΪÁËÕâÏî¼¼Êõ´óÃæ»ý±é¼°µÄÆ¿¾±µØµã¡£¶øÌåÄÚCART(in vivo CAR-T)ÔòÒԵ߸²ÐԵļ¼Êõ£¬Í¨¹ýÌØÊâÔØÌ彫CAR»ùÒòÖ±½ÓËÍÈëÌåÄÚ£¬Ìø¹ý·±ËöµÄÌå±í²½Ö裬ֱ½ÓÔÚ»¼ÕßÌåÄÚʵÏÖ¶ÔTϸ°ûµÄ“É豸Éý¼¶”£¬³ÉΪÏÂÒ»´úϸ°ûÃâÒßÒ½ÖεÄÆƾֵã¡£

¡¡¡¡2025Äê6ÔÂ11ÈÕ£¬Ê¹ÓÃLNPΪÖØÒªµÝËÍÔØÌåµÄin vivo CAR-TÁÆ·¨¹«Ë¾Capstan°ä·¢£¬ÆäÒÔרÓм¼ÊõtLNP(ÌåÄÚ°ÐÏòÖ¬ÖÊÄÉÃ׿ÅÁ£)ΪÔØÌåµÄin vivo CAR-Tϸ°ûÁÆ·¨CPTX2309ÕýʽÆðÍ·¢ñÆÚÁÙ´²ÊÔÑ飬ÓÃÓÚÒ½ÖÎBϸ°û½éµ¼µÄ×ÔÉíÃâÒß¼²²¡1¡£Ëæºó£¬2025Äê6ÔÂ30ÈÕ£¬°¬²®Î¬ÓëCapstan°ä¸»Ç¿³É×îÖÕºÍ̸£¬°¬²®Î¬½«ÒÔ21ÒÚÃÀÔªµÄ¼ÛÖµÊÕ¹ºCapstan£¬Õâ´ÎÊÕ¹ºº­¸ÇÆä¸Õ½øÈë¢ñÆÚÁÙ´²ÊÔÑéµÄCPTX23092¡£Í¬Ê±£¬°¬²®Î¬»¹½«»ñµÃCapstanµÄtLNPƽ̨¼¼Êõ£¬¸Ã¼¼ÊõÖ¼ÔÚµÝËÍRNAÓÐЧÔغÉ(ÈçmRNA)£¬¿ÉÄÜÔÚÌåÄÚ¶ÔÌض¨Ï¸°ûÀàÐͽøÐй¤³ÌˢС£

ec752f51-894c-411f-8ad0-8797d5d1fac5

¡¡¡¡ÄÉÃ×¼¼ÊõµÄ·ÉËÙ·¢Õ¹ÎªÒ©ÎïµÝËÍϵͳ´øÀ´Á˸ïÃüÐÔµÄÍ»ÆÆ¡£ÒÔCapstanµÄ¼¼Êõƽ̨ΪÀý£¬ÔÚÔ챸LNPʱ»ìÈëÒÔÂíÀ´õ£ÑÇ°·»ùÍÅ(-Maleimide£¬MAL)µÄPEGÖ¬£¬´ýLNPÔ챸ʵÏÖºó£¬ÔÙ½«´øÓÐÛÏ»ù(-SH)µÄ¿¹Ìåͨ¹ý·õÓýµÄ·½Ê½Å¼ÁªÔÚº¬ÓÐMAL»ùÍŵÄPEGÖ¬ÉÏ£¬¼´¿É¸³ÓèLNPϵͳ“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£

¡¡¡¡DSPE-PEG2000-MAL(1,2-¶þÓ²Ö¬õ£-sn-¸ÊÓÍ-3-Á×ËáÒÒ´¼°·-¾ÛÒÒ¶þ´¼2000-ÂíÀ´õ£ÑÇ°·)×÷ΪһÖÖÉè¼Æ¾«²ÊµÄÖ°ÄÜ»¯Á×Ö¬-PEGÑÜÉúÎÒѳÉΪ¹¹½¨ÏȽøÄÉÃ×ÔØÌåµÄ³ÁÒª´´ÐÂ×ÊÁÏÖ®Ò»¡£Æä¹ÖÒìµÄ·Ö×ӽṹ¸³ÓèÁËÔØÌ峤ѭ»·¡¢×Ô¶¯°ÐÏò¼°¶àÖ°Äܼ¯³É»¯µÄÄÜÁ¦£¬ÔÚ°ÐÏòÒ½ÖΡ¢·Ö×ÓÓ°ÏñºÍÃâÒßÁÆ·¨µÈÁìÓòչʾ³ö¾Þ´óµÄÀûÓÃDZÁ¦¡£

¡¡¡¡·Ö×ӽṹÓëÀí»¯¸öÐÔ

¡¡¡¡DSPE-PEG2000-MALµÄ·Ö×ÓÁ¿Ô¼Îª2805–3000Da£¬ÖØÒªÔ̺¬Èý¸öÖ°ÄÜÃ÷È·µÄÄ£¿é£º

¡¡¡¡DSPE(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine)Êèˮ궨»ùÍÅ£º×÷ΪÁ½Ç×ÐÔ·Ö×ÓµÄÊèˮβ²¿£¬DSPEº¬ÓÐÁ½ÌõC18¹ÄºÍÖ¬·¾ËáÁ´£¬Æä½á¹¹Óëϸ°ûĤÁ×֬˫·Ö×Ó²ãÓµÓи߶ÈÇ׺ÍÐÔ£¬¿ÉÄܲ»±äµØǶÈëÖ¬ÖÊÌåĤ»ò×é³É½ºÊøµÄÊèË®Äںˣ¬ÎªÕû¸ö·Ö×ÓÌṩÀι̵Ä궨×÷Óá£

¡¡¡¡PEG2000(Polyethyleneglycol)Ç×Ë®Á´¶Î£º·Ö×ÓÁ¿Ô¼Îª2000DaµÄ¾ÛÒÒ¶þ´¼Á´×é³ÉÁË·Ö×ÓµÄÇ×Ë®¹Ú²ã¡£ÔÚÉúÀí»·¾³ÖУ¬PEGÁ´Í¨¹ý¿Õ¼äλ×èЧӦºÍË®ºÏ×÷Óã¬ÔÚÄÉÃ×ÔØÌå±í±íÐγÉÒ»²ãÖÂÃܵēˮ»¯ÔÆ”£¬ÓÐЧÏ÷¼õѪ½¬µ°°×µÄÎü¸½£¬´Ó¶ø¶ã±ÜÍø×´ÄÚƤϵͳµÄ¼±¾ç¶Ï¸ù¡£ÕâÒ»¸öÐÔ£¬¼´“ÒþÐÎЧӦ”(Stealth®effect)£¬Êǵ¢¸éÔØÌåÌåÄÚÑ­»·°ëË¥ÆڵĹؼü¡£

¡¡¡¡MAL(Maleimide)»îÐÔ½áβ»ùÍÅ£ºÂíÀ´õ£ÑÇ°·»ùÍÅÊÇ·Ö×ӵķ´Ó³»îÐÔÖÐÐÄ¡£ËüÄÜÔÚpH6.5-7.2µÄÇ°ÌáÏ£¬ÓëÛÏ»ù(-SH£¬Áò´¼)²úÉú¸ßЧ¡¢ÌØÒìÐÔµÄÂõ¿Ë¶û¼Ó³É·´Ó³£¬Ðγɲ»±äµÄÁòÃѹ²¼Û¼ü¡£ÕâÒ»»¯Ñ§Ñ¡ÔñÐÔʹÆä³ÉΪÏνӺ¬°ëë×°±Ëá²Ð»ùµÄ°ÐÏòÅäÌå(È翹Ìå¡¢¶àëÄ¡¢ÊÊÅäÌå)µÄÃÎÏë“»¯Ñ§×¥ÊÖ”¡£

5ae39068-8d09-4d8f-96b6-aa61c69d5731       

ÏîÄ¿ ÃèÊö
±í¹Û °×É«»òÀà°×É«À¯×´¹ÌÌå
ÈÜ»¯ÐÔ ¿ÉÔÚDMSO¡¢ÒÒ´¼¡¢ÎÂË®ÖзÖÉ¢»òÈÜ»¯
pH²»±äÐÔ pH 6.5-7.2½Ï²»±ä£¨Ô¤·ÀMaleimideË®½â£©
ÀûÓà ֬ÖÊÌ彨ÊΡ¢ÉúÎïżÁª¡¢°ÐÏòµÝË͵È

       ÔÚʹÓÃDSPE-PEG2000-MALµÄµÝËÍϵͳÖУ¬DSPE¶Ë²åÈëÁ×֬˫·Ö×Ӳ㣬PEGÁ´ÑÓ³¤ÖÁ±í²¿Ë®Ï࣬ÏÔÖøÌáÉýÁËϵͳµÄ²»±äÐÔºÍÌåÄÚÑ­»·¶¯Á¦Ñ§¡£ÀýÈ磬¾­PEG½¨ÊεÄÖ¬ÖÊÌå(ÈçDoxil®)°ëË¥ÆÚ¿É´ÓÊýÓ×ʱµ¢¸éÖÁÔ¼55Ó×ʱ£¬²¢½èÖú¼ÓÇ¿ÉøÈëÖÍÁôЧӦÔÚÖ×Áö²¿Î»ÊµÏÖ±»¶¯¸»¼¯3¡£¶øMAL»ùÍÅÄÜÓ뺬ÛÏ»ù(-SH)·Ö×Ó¶¨ÏòżÁªµÄ¸öÐÔ£¬¸³ÓèÆä“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£ÔÚ½ºÊøϵͳÖУ¬DSPE-PEG2000-MALÒ²¿É×Ô×é×°ÐγɺË-¿Ç½á¹¹£¬ÊèË®µÄDSPEÄÚºËÓÃÓÚÔöÈÜ×Ïɼ´¼µÈÄÑÈÜÐÔ»¯ÁÆÒ©Î¶øPEG±í¿ÇºÍMALÖ°ÄÜ»¯±í±íÔòͬÑùÌṩ²»±äÐÔºÍ×Ô¶¯°ÐÏòµÄDZÁ¦£¬ÍØÕ¹mRNAÒ©ÎïµÄÀûÓÃÁìÓò£¬ÊµÏÖ¸ü¾«×¼µÄϸ°ûÀàÐÍÌØÒìÐÔµÝËÍ¡£

¡¡¡¡DSPE-PEG2000-MALƾ½èÆä“궨-ÒþÐÎ-ÏνӔÈýλһÌåµÄ·Ö×ÓÉè¼Æ£¬ÒѳÉΪ¾«×¼Ò©ÎïµÝËÍÁìÓò²»³É»òȱµÄÖ°ÄÜ×ÊÁÏ¡£Ëü²»½ö½â¾öÁËÄÉÃ×ÔØÌåÔÚÌåÄڵIJ»±äÐԺͳ¤Ñ­»·ÎÊÌ⣬¸ü³ÁÒªµÄÊÇ£¬Í¨¹ýÆä¸ß¶ÈÌØÒìÐԵĻ¯Ñ§Å¼ÁªÄÜÁ¦£¬ÊµÏÖÁ˶ÔÄÉÃ×ÔØÌåµÄ±í±íÖ°ÄÜ»¯£¬´Ó¶ø¸³ÓèÆä×Ô¶¯°ÐÏò¡¢ÖÇÄÜÏìÓ¦ºÍÕïÁÆÒ»Ì廯µÈ¸ß¼¶Ö°ÄÜ¡£Ëæ×ŶÔÃâÒßÉúÎïѧ»úÔìµÄÉî¿ÌË÷Çó£¬DSPE-PEG2000-MAL¼°ÆäÑÜÉúÎｫ³ÖÐø×÷Ϊ¹¹½¨¸´ÔÓ¡¢¸ßЧ¡¢ÖÇÄÜÄÉÃ×Ò©ÎïϵͳµÄ³ÁÒª»ùʯ֮һ£¬Îª¹¥¿Ë³Á´ó¼²²¡Ò½ÖÎÖеĸ÷ÀàÌôÕ½ÌṩǿÓÐÁ¦µÄ¼¼ÊõÖ§³Ö£¬Íƶ¯¾«×¼Ò½ÁÆÂõÏòеĸ߶È¡£

¡¡¡¡×÷ΪרһÓÚÒ©ÎïµÝËͼ¼ÊõµÄ´´ÐÂÐÍÆóÒµ£¬9888À­Ë¹Î¬¼Ó˹¿Æ¼¼±ü³Ð“ÒÔ×ÊÁÏ´´ÐÂÒýÁìÉúÎïÒ½Ò©´´Ð“µÄ×ÚÖ¼£¬ÒÀ¸½×ÔÉíÔÚÒ©ÎïµÝËÍÁìÓòµÄÖÕÄê¶Ñ¼¯Óë´´ÐÂÓÅÊÆ£¬¿ÉΪÄúÌṩÇкÏÑз¢¼°ÖбíÉ걨ÐèÒªµÄDSPE-PEG2000-MAL²úÆ·£¬²¢ÎªÈ«ÇòºÏ×÷ͬ°éÔÚºóÐøµÄ×êÑÐÓëÀûÓùý³ÌÖУ¬ÌṩÔçÄêÆÚÑз¢µ½ºóÆÚת»¯µÄÈ«Á÷³ÌÖ§³Ö¡£

¡¡¡¡²Î¿¼Îļþ

¡¡¡¡1 WIRE, B. Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease, <https://www.businesswire.com/news/home/20250611668181/en/Capstan-Therapeutics-Announces-Initiation-of-Phase-1-Trial-of-Lead-In-Vivo-CAR-T-Therapy-CPTX2309-for-Treating-Autoimmune-Disease> (2025).

¡¡¡¡2 AbbVie. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology, <https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology> (2025).

¡¡¡¡3 Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54, 987-992 (1994).

¹Ø¼ü´Ê£º

ÍƼöÐÂÎÅ

¡¾9888À­Ë¹Î¬¼Ó˹´È±¯¡¿À´µÃÒâɽµÄÀñÎï

2026-02-10

ϲ±¨ | ÁÉÄþ9888À­Ë¹Î¬¼Ó˹¿Æ¼¼ÓÐÏÞ¹«Ë¾ÈëÑ¡ÁÉÄþʡר¾«ÌØÐÂÖÐÓ×ÆóÒµ

2026-01-30

·ÖÏíµ½

¡¾ÍøÕ¾µØͼ¡¿